# Clinical effects of chemotherapy combined with Bevacizumab and Olaparib in treating advanced ovarian cancer and its effect on serum tumor markers and T-lymphocyte functions

## TL;DR

This study shows that combining chemotherapy with bevacizumab and olaparib improves outcomes in advanced ovarian cancer by boosting immune function and reducing tumor markers.

## Contribution

The novel contribution is demonstrating the combined clinical benefits of bevacizumab and olaparib with chemotherapy in advanced ovarian cancer.

## Key findings

- The study group had a significantly higher overall response rate (92%) compared to the control group (68%).
- Tumor markers like CA153, CA125, and CA199 were significantly lower in the study group after treatment.
- The study group showed improved T-lymphocyte markers (CD3+, CD4+, CD4+/CD8+) compared to the control group.

## Abstract

To evaluate the clinical efficacy of chemotherapy combined with bevacizumab and olaparib in treating advanced ovarian cancer and investigate the effect of such combination treatment on serum tumor markers and T-lymphocyte function.

This was a retrospective study. A total of 120 patients with advanced ovarian cancer admitted to Baoding Second Hospital and Baoding First Central Hospital from January 2022 to June 2024 were randomly divided into two groups(n= 60 each group): the control group received standard paclitaxel and carboplatin chemotherapy(TP regimen), while the study group was administered bevacizumab infusions and oral olaparib, in addition to the exact treatment provided for the control group. Comparisons were made between the two groups regarding the clinical efficacy and adverse drug reactions.

The overall response rate was 92% and 68% in the study group and the control group, respectively, suggesting a difference of statistical significance(p=0.00). Furthermore, post-treatment levels of CA153, CA125, CA199, and other markers were significantly lower in the study group than in the control group(all p= 0.00). Meanwhile, the post-treatment levels of CD3+, CD4+, and CD4+/CD8+ were significantly higher in the study group compared to the control group (all p = 0.00). Moreover, the post-treatment levels of TNF-a, CRP, IL-6, and other markers were significantly lower in the study group than in the control group (all p= 0.00).

The combined use of conventional chemotherapy, bevacizumab, and olaparib demonstrates significant clinical efficacy in the treatment of advanced ovarian cancer, which can improve cellular immune function, lower tumor marker levels.